Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: The BENEDICT-B randomized trial

Piero Ruggenenti, Anna Fassi, Aneliya Parvanova Ilieva, Ilian Petrov Iliev, Carlos Chiurchiu, Nadia Rubis, Giulia Gherardi, Bogdan Ene-Iordache, Flavio Gaspari, Annalisa Perna, Paolo Cravedi, Antonio Bossi, Roberto Trevisan, Nicola Motterlini, Giuseppe Remuzzi

Research output: Contribution to journalArticlepeer-review

Abstract

Objectives: To address whether nondihydropyridine calcium-channel blocker added-on angiotensin-converting-enzyme inhibitor therapy ameliorates albuminuria and cardiovascular outcomes in type 2 diabetes patients. Design: The Bergamo Nephrologic Diabetes Complications Trial-B was a multicentre, prospective, double-blind, parallel-group trial comparing renal and cardiovascular outcomes in 281 hypertensive type 2 diabetes patients with microalbuminuria randomized to at least 2-year VeraTran (verapamil/trandolapril 180 mg/2 mg daily) or trandolapril (2 mg daily, identical image) treatment. Main outcome was persistent macroalbuminuria (albuminuria >200 μg/min in two consecutive visits). Treatment targets were SBP/DBP less than 120/80 mmHg and HbA1C less than 7%. Results: Over a median follow-up of 4.5 years, 18 patients (13%) on VeraTran vs. 15 (10.5%) on trandolapril [unadjusted hazard ratio (95% confidence interval [CI]) 1.07 (0.54-2.12), P = 0.852] progressed to macroalbuminuria, respectively; 62 (44.9%) vs. 71 (49.7%) [0.80 (0.57-1.12), P = 0.198] regressed to normoalbuminuria (urinary albumin excretion

Original languageEnglish
Pages (from-to)207-216
Number of pages10
JournalJournal of Hypertension
Volume29
Issue number2
DOIs
Publication statusPublished - Feb 2011

Keywords

  • cardioprotection
  • cardiovascular events
  • hypertension
  • macroalbuminuria
  • microalbuminuria
  • nephroprotection
  • normoalbuminuria
  • progression
  • regression
  • type 2 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Physiology
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: The BENEDICT-B randomized trial'. Together they form a unique fingerprint.

Cite this